Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 18/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 18/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 18/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1155847 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL635187 | 0.88 | SLC6A4 (0.78) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL635189 | 0.88 | SLC6A4 (0.78) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL635188 | 0.88 | SLC6A4 (0.78) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL1156221 | 0.88 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL1156224 | 0.88 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL634687 | 0.86 | SLC6A4 (0.75) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL634480 | 0.86 | SLC6A4 (0.75) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL634479 | 0.86 | SLC6A4 (0.75) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL634478 | 0.86 | SLC6A4 (0.75) | SLC6A2SLC6A4SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933249-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933249-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933249-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2318362-B1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE INC (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2318362-B1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE INC (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8242164-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242164-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110275694-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275694-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275694-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-7888386-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888386-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888386-B2 | 3-(phenoxyphenylmethyl)pyrrolidine compounds | THERAVANCE, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| WO-2010011811-A2 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178509-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | HTR6, SLC6A2, SLC6A4 | SLC6A2 2/4885SLC6A4 3/4885SLC6A3 4/4885 |
| US-20110275694-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | HTR6, SLC6A2, SLC6A4 | SLC6A2 2/4885SLC6A4 3/4885SLC6A3 4/4885 |
| US-20100022616-A1 | 3-(PHENOXYPHENYLMETHYL)PYRROLIDINE COMPOUNDS | HTR6, SLC6A2, SLC6A4 | SLC6A2 2/4885SLC6A4 3/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.